within Pharmacolibrary.Drugs.ATC.L;

model L01XF01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.015000000000000001,
    adminDuration  = 600,
    adminMass      = 45 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 1320,            
    Vdp             = 0.0025,
    k12             = 180,
    k21             = 180
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XF01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tretinoin (all-trans retinoic acid) is a derivative of vitamin A used primarily in the treatment of acute promyelocytic leukemia (APL) as a differentiation agent under the ATC code L01XF01. Its use in oncology is distinct from topical use for acne or dermatology. It is approved for intravenous and oral administration in acute promyelocytic leukemia.</p><h4>Pharmacokinetics</h4><p>Reported for adult patients with acute promyelocytic leukemia receiving oral tretinoin therapy.</p><h4>References</h4><ol><li><p>Fitton, A, &amp; Goa, KL (1991). Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. <i>Drugs</i> 41(5) 780–798. DOI:<a href=\"https://doi.org/10.2165/00003495-199141050-00007\">10.2165/00003495-199141050-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1712709/\">https://pubmed.ncbi.nlm.nih.gov/1712709</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Kovacs, P (2012). Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics. <i>Expert review of clinical pharmacology</i> 5(4) 373–388. DOI:<a href=\"https://doi.org/10.1586/ecp.12.26\">10.1586/ecp.12.26</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22943117/\">https://pubmed.ncbi.nlm.nih.gov/22943117</a></p></li><li><p>Veraldi, S, et al., &amp; Barbareschi, M (2016). Are topical retinoids teratogenic?. <i>Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia</i> 151(6) 700–705. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27598619/\">https://pubmed.ncbi.nlm.nih.gov/27598619</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XF01;
